Skip to main navigation Skip to search Skip to main content

Surgical options after Fontan failure

  • Joost P. Van Melle
  • , Djoeke Wolff
  • , Jürgen Hörer
  • , Emre Belli
  • , Bart Meyns
  • , Massimo Padalino
  • , Harald Lindberg
  • , Jeffrey P. Jacobs
  • , Ilkka P. Mattila
  • , Håkan Berggren
  • , Rolf M.F. Berger
  • , Rene Prêtre
  • , Mark G. Hazekamp
  • , Morten Helvind
  • , Matej Nosál
  • , Tomas Tlaskal
  • , Jean Rubay
  • , Stojan Lazarov
  • , Alexander Kadner
  • , Viktor Hraska
  • José Fragata, Marco Pozzi, George Sarris, Guido Michielon, Duccio Di Carlo, Tjark Ebels
  • University Medical Center Groningen
  • University Medical Centre Groningen
  • Centre Chirurgical Marie Lannelongue
  • Katholieke Universiteit Leuven
  • University of Padova
  • Rikshospitalet-Radiumhospitalet HF
  • All Children's Hospital St. Petersburg
  • Johns Hopkins University
  • University of Helsinki
  • Queen Silvia Children's Hospital
  • University Hospital Zurich
  • Leiden University Medical Centre
  • Amsterdam University Medical Centers
  • Copenhagen University Hospital
  • National Institute of Cardiovascular Diseases Slovakia
  • Charles University and Motol University Hospital
  • Clinique Universitaire St-Luc
  • National Heart Hospital
  • Inselspital Universitatsspital
  • German Pediatric Heart Centre
  • Hospital de Santa Marta
  • Riuniti Hospital
  • Athens Heart Surgery Institute
  • Iaso General Hospital of Thessalia Larisa
  • Ospedale Pediatrico Bambino Gesù

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Objective The objective of this European multicenter study was to report surgical outcomes of Fontan takedown, Fontan conversion and heart transplantation (HTX) for failing Fontan patients in terms of all-cause mortality and (re-)HTX. Methods A retrospective international study was conducted by the European Congenital Heart Surgeons Association among 22 member centres. Outcome of surgery to address failing Fontan was collected in 225 patients among which were patients with Fontan takedown (n=38; 17%), Fontan conversion (n=137; 61%) or HTX (n=50; 22%). Results The most prevalent indication for failing Fontan surgery was arrhythmia (43.6%), but indications differed across the surgical groups (p<0.001). Fontan takedown was mostly performed in the early postoperative phase after Fontan completion, while Fontan conversion and HTX were mainly treatment options for late failure. Early (30 days) mortality was high for Fontan takedown (ie, 26%). Median follow-up was 5.9 years (range 0-23.7 years). The combined end point mortality/HTX was reached in 44.7% of the Fontan takedown patients, in 26.3% of the Fontan conversion patients and in 34.0% of the HTX patients, respectively (log rank p=0.08). Survival analysis showed no difference between Fontan conversion and HTX (p=0.13), but their ventricular function differed significantly. In patients who underwent Fontan conversion or HTX ventricular systolic dysfunction appeared to be the strongest predictor of mortality or (re-)HTX. Patients with valveless atriopulmonary connection (APC) take more advantage of Fontan conversion than patients with a valve-containing APC (p=0.04). Conclusions Takedown surgery for failing Fontan is mostly performed in the early postoperative phase, with a high risk of mortality. There is no difference in survival after Fontan conversion or HTX.

Original languageEnglish
Pages (from-to)1127-1133
Number of pages7
JournalHeart
Volume102
Issue number14
DOIs
StatePublished - 15 Jul 2016

Fingerprint

Dive into the research topics of 'Surgical options after Fontan failure'. Together they form a unique fingerprint.

Cite this